Drugs / MK-3402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04678505 | Feb → Apr 2021 | impaired renal function disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04678505 ↗ |
| Route | Intravenous | “MK-3402 administered as a single dose of 100 mg IV infusion” NCT04678505 ↗ |